Literature DB >> 27261479

Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung Adenocarcinomas.

Paul K Paik1.   

Abstract

Mutations in EGFR stand as the archetype for somatic alterations that lead to oncogene addiction and that predict for response to targeted therapies. In this issue of Cancer Discovery, Konduri and colleagues report on a pair of novel oncogenic and actionable EGFR fusion events in a series of patients with lung adenocarcinomas, casting new light on this model gene. Cancer Discov; 6(6); 574-5. ©2016 AACRSee related article by Konduri et al., p. 601. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27261479      PMCID: PMC4894533          DOI: 10.1158/2159-8290.CD-16-0478

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  10 in total

1.  Crystal structure of a Rad51 filament.

Authors:  Adam B Conway; Thomas W Lynch; Ying Zhang; Gary S Fortin; Cindy W Fung; Lorraine S Symington; Phoebe A Rice
Journal:  Nat Struct Mol Biol       Date:  2004-07-04       Impact factor: 15.369

2.  Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.

Authors:  Jeonghee Cho; Sandra Pastorino; Qing Zeng; Xiaoyin Xu; William Johnson; Scott Vandenberg; Roel Verhaak; Andrew D Cherniack; Hideo Watanabe; Amit Dutt; Jihyun Kwon; Ying S Chao; Robert C Onofrio; Derek Chiang; Yuki Yuza; Santosh Kesari; Matthew Meyerson
Journal:  Cancer Res       Date:  2011-10-14       Impact factor: 12.701

3.  Hydrodynamic studies on the quaternary structure of recombinant mouse Purbeta.

Authors:  Jon E Ramsey; Margaret A Daugherty; Robert J Kelm
Journal:  J Biol Chem       Date:  2006-11-22       Impact factor: 5.157

4.  FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.

Authors:  Rui Wang; Lei Wang; Yuan Li; Haichuan Hu; Lei Shen; Xuxia Shen; Yunjian Pan; Ting Ye; Yang Zhang; Xiaoyang Luo; Yiliang Zhang; Bin Pan; Bin Li; Hang Li; Jie Zhang; William Pao; Hongbin Ji; Yihua Sun; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

5.  EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Authors:  Kartik Konduri; Jean-Nicolas Gallant; Young Kwang Chae; Francis J Giles; Barbara J Gitlitz; Kyle Gowen; Eiki Ichihara; Taofeek K Owonikoko; Vijay Peddareddigari; Suresh S Ramalingam; Satyanarayan K Reddy; Beth Eaby-Sandy; Tiziana Vavalà; Andrew Whiteley; Heidi Chen; Yingjun Yan; Jonathan H Sheehan; Jens Meiler; Deborah Morosini; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali; Christine M Lovly
Journal:  Cancer Discov       Date:  2016-04-21       Impact factor: 39.397

6.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Authors:  Paul K Paik; Alexander Drilon; Pang-Dian Fan; Helena Yu; Natasha Rekhtman; Michelle S Ginsberg; Laetitia Borsu; Nikolaus Schultz; Michael F Berger; Charles M Rudin; Marc Ladanyi
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

7.  A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

Authors:  Young Seok Ju; Won-Chul Lee; Jong-Yeon Shin; Seungbok Lee; Thomas Bleazard; Jae-Kyung Won; Young Tae Kim; Jong-Il Kim; Jin-Hyoung Kang; Jeong-Sun Seo
Journal:  Genome Res       Date:  2011-12-22       Impact factor: 9.043

Review 8.  Epidermal growth factor receptor: mechanisms of activation and signalling.

Authors:  Robert N Jorissen; Francesca Walker; Normand Pouliot; Thomas P J Garrett; Colin W Ward; Antony W Burgess
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

9.  Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Authors:  Kurtis D Davies; Anh T Le; Mariana F Theodoro; Margaret C Skokan; Dara L Aisner; Eamon M Berge; Luigi M Terracciano; Federico Cappuzzo; Matteo Incarbone; Massimo Roncalli; Marco Alloisio; Armando Santoro; D Ross Camidge; Marileila Varella-Garcia; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2012-08-23       Impact factor: 12.531

10.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.